quantisnow
FeedTopReportsPricing
⌘K
Live feed
09:03:06·36d
INSIDERFiling
Adagene Inc. logo

SEC Form 3 filed by Adagene Inc.

ADAG· Adagene Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • ADAG
    Adagene Inc.
    Health Care

Recent analyst ratings

  • Nov 24UpdateGuggenheim$9.00
  • Aug 6UpdateLeerink Partners$7.00
  • Jan 31UpdateMorgan Stanley-
  • Feb 1UpdateMorgan Stanley$15.00

Related

  • SEC6d
    SEC Form 6-K filed by Adagene Inc.
  • PR6d
    Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor Types
  • PR9d
    Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board
  • SEC21d
    SEC Form 424B5 filed by Adagene Inc.
  • SEC21d
    SEC Form 6-K filed by Adagene Inc.
  • PR21d
    Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
  • SEC21d
    SEC Form 424B5 filed by Adagene Inc.
  • PR21d
    Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022